Empagliflozin Protects At-Risk Patients From CKD Progression
(MedPage Today) -- Empagliflozin (Jardiance) reduced the risks of chronic kidney disease (CKD) progression and cardiovascular-related deaths in high-risk patients compared with placebo, the phase III EMPA-KIDNEY trial showed.
Over a median 2-year...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Empagliflozin | Heart | Jardiance | Urology & Nephrology